FTLD-TDP病理亚型的遗传结构
Oriol Dols-Icardo1, Lianne M Reus2, Alfredo Ramirez3
1Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
Trends in neurosciences
|July 3, 2025
概括
研究人员确定了TDP-43聚合 (FTLD-TDP) 亚型的前叶退化遗传风险因素. 这项研究提高了对FTLD-TDP异质性和潜在机制的理解.
科学领域:
- 神经遗传学 神经遗传学
- 神经退行性疾病 神经退行性疾病
- 分子生物学分子生物学
背景情况:
- 带有TDP-43聚合 (FTLD-TDP) 的前叶退化是痴呆的主要原因.
- FTLD-TDP亚型的遗传基础在很大程度上是未知的.
- 鉴定遗传因素对于了解疾病机制至关重要.
研究的目的:
- 识别与不同的FTLD-TDP亚型相关的常见和罕见遗传变异.
- 为FTLD-TDP的遗传结构提供新的见解.
- 基于遗传因素来探索FTLD-TDP的异质性.
主要方法:
- 使用全基因组关联研究 (GWAS).
- 分析包括了常见和罕见的遗传变异.
- 使用统计方法将变体与FTLD-TDP亚型联系起来.
主要成果:
- 确定了与特定的FTLD-TDP亚型相关的常见和罕见遗传变异.
- 发现了有助于FTLD-TDP异质性的新型遗传关联.
- 这些发现揭示了涉及FTLD-TDP的分子通路.
结论:
- 在FTLD-TDP的不同亚型中,遗传因素起着重要作用.
- 鉴定到的变异为研究FTLD-TDP提供了新的目标.
- 了解基因异质性是开发针对FTLD-TDP的向治疗的关键.
相关概念视频
Sex Linked Disorders
Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...


